National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Lip and Oral Cavity Cancer Treatment (PDQ®)
Patient Version   Health Professional Version   En español   Last Modified: 05/22/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information






Treatment Option Overview






Stage I Lip and Oral Cavity Cancer






Stage II Lip and Oral Cavity Cancer






Stage III Lip and Oral Cavity Cancer






Stage IV Lip and Oral Cavity Cancer






Recurrent Lip and Oral Cavity Cancer






Get More Information From NCI






Changes to This Summary (05/22/2008)






More Information



Page Options
Print This Page
Print Entire Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Recurrent Lip and Oral Cavity Cancer

Current Clinical Trials

For lesions of the lip, anterior tongue, buccal mucosa, floor of mouth, retromolar trigone, upper gingiva, and hard palate, treatment will be dictated by the location and size of the recurrent lesion as well as prior treatment.[1,2]

Standard treatment options:

  1. If radiation therapy was used initially, surgery is the preferred treatment.[3]
  2. If surgery was used to treat the lesion initially, surgery,[3] radiation therapy, or a combination of these may be considered.
  3. Although chemotherapy has been shown to induce responses, no increase in survival has been demonstrated.[4]

Treatment options under clinical evaluation:

  • Because surgical salvage after primary treatment by radiation therapy and radiation therapy after primary surgery give poor results, clinical trials evaluating new chemotherapy drugs, chemotherapy and reirradiation, or hyperthermia should be considered.[5,6]
Current Clinical Trials

Check for U.S. clinical trials from NCI's PDQ Cancer Clinical Trials Registry that are now accepting patients with recurrent lip and oral cavity cancer. The list of clinical trials can be further narrowed by location, drug, intervention, and other criteria.

General information about clinical trials is also available from the NCI Web site.

References

  1. Harrison LB, Sessions RB, Hong WK, eds.: Head and Neck Cancer: A Multidisciplinary Approach. Philadelphia, Pa: Lippincott-Raven, 1999. 

  2. Vikram B, Strong EW, Shah JP, et al.: Intraoperative radiotherapy in patients with recurrent head and neck cancer. Am J Surg 150 (4): 485-7, 1985.  [PUBMED Abstract]

  3. Wong LY, Wei WI, Lam LK, et al.: Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck 25 (11): 953-9, 2003.  [PUBMED Abstract]

  4. Jacobs C, Lyman G, Velez-García E, et al.: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10 (2): 257-63, 1992.  [PUBMED Abstract]

  5. Hong WK, Bromer R: Chemotherapy in head and neck cancer. N Engl J Med 308 (2): 75-9, 1983.  [PUBMED Abstract]

  6. Vokes EE, Athanasiadis I: Chemotherapy of squamous cell carcinoma of head and neck: the future is now. Ann Oncol 7 (1): 15-29, 1996.  [PUBMED Abstract]

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov